WP
KYTX icon

Woodline Partners’s Kyverna Therapeutics KYTX Stock Holding History

Woodline Partners’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.53M Hold
845,325
– – 0.02% 600
2026
Q1 		$7.3M Buy
845,325
+182
+0% +$1.52K 0.03% 586
2025
Q4 		$7.94M Buy
845,143
+592,931
+235% +$4.4M 0.03% 521
2025
Q3 		$1.51M Buy
+252,212
New +$1.01M 0.01% 761
2024
Q4 		– Sell
-42,477
Closed -$208K – 1012
2024
Q3 		$208K Sell
42,477
-90,423
-68% -$697K ﹤0.01% 574
2024
Q2 		$997K Sell
132,900
-260,028
-66% -$3.97M 0.01% 462
2024
Q1 		$9.76M Buy
+392,928
New +$11M 0.09% 275

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return

Woodline Partners's KYTX Position: Q2 2026 in Review

Woodline Partners held its Kyverna Therapeutics (KYTX) position steady in Q2 2026 at 845,325 shares worth $7.53M. The position accounts for 0.02% of the portfolio, ranked #600.

Woodline Partners first reported a position in KYTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $9.76M in Q1 2024. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • Woodline Partners held 845,325 shares of Kyverna Therapeutics worth $7.53M as of Q2 2026.
  • Woodline Partners left its Kyverna Therapeutics share count unchanged in Q2 2026.
  • Kyverna Therapeutics made up 0.02% of Woodline Partners's portfolio in Q2 2026, its #600 holding.
  • Woodline Partners first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Woodline Partners's Kyverna Therapeutics position peaked at $9.76M in Q1 2024.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.